Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues - 2Popular Home Rug Series For You
- 3Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- 4The most effective method to Shake Hands During a Pandemic: Wellbeing Tips and Behavior
- 5Carry Nature Inside with These Staggering Plant Decisions
- When preventable infections turn deadly behind bars | The Excerpt
- Russia provided Iran with list of Israeli energy targets, Ukrainian intelligence finds
- Couch Styles of 2024: What's Moving
- Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
- NASA shares first photos of Earth taken by Artemis II
- Remote Headphones: Upgrade Your Sound Insight
- St George Mining hits record 178m high-grade intercept at Araxá, reinforcing global scale
- The Specialty of Cleaning up: Change Your Space and Brain
- Rescuers attempt to dig free whale stranded on Germany's Baltic coast
